PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28521419-3	2017	The present study examined the protein expression of excision repair cross-complementation group 1 (ERCC1) and class III beta-tubulin (TUBB3), which are consider to be indicators of the anticancer activity of platinum-based and taxane-based chemotherapy, respectively.	taxane	228-234	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	53-98	
31405143-0	2019	ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers.	taxane	53-59	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5	
31405143-8	2019	However, in patients with ER-tumours who received additional neoadjuvant taxane, high ERCC1 transcript was associated with a higher pCR and decreased DRR.	taxane	73-79	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	86-91	
31405143-9	2019	High ERCC1 transcript was also linked to decreased DRR in ER+ LABC that received additional neoadjuvant taxane.	taxane	104-110	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	5-10	
28521419-3	2017	The present study examined the protein expression of excision repair cross-complementation group 1 (ERCC1) and class III beta-tubulin (TUBB3), which are consider to be indicators of the anticancer activity of platinum-based and taxane-based chemotherapy, respectively.	taxane	228-234	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	100-105	
20047843-5	2010	In non-small cell lung cancer (NSCLC), the strongest clinical evidence is for taxane resistance with elevated expression or mutation of class III beta-tubulin (and possibly alpha tubulin), platinum resistance and expression of ERCC1 or BCRP, gemcitabine resistance and RRM1 expression, and resistance to several agents and COX-2 expression (although COX-2 inhibitors have had minimal impact on drug efficacy clinically).	taxane	78-84	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	227-232	
23482788-7	2013	CONCLUSION: Patients with simultaneous low expression of ERCC1 and tubulin are promising candidates for surgery after carboplatin-taxane chemoradiotherapy.	taxane	130-136	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	57-62	
21289518-7	2011	We also found that overexpression of ERCC1 and TUBB3 was associated with resistance to platinum- and taxane-based chemotherapy.	taxane	101-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	37-42	
21289518-9	2011	High-ERCC1 and TUBB3 expressions might be associated with resistance to platinum- and taxane-based chemotherapy, respectively.	taxane	86-92	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	5-10	
22993560-0	2010	Expression of ERCC1 and class III beta-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane.	taxane	196-202	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19	
18395930-9	2008	In conclusion, we found that the loss of ERCC1 and class III beta-tubulin protein expression were predictors of better survival in patients who received a platinum-based plus taxane chemotherapy.	taxane	175-181	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	41-46	
19683826-11	2010	However, only ERCC1 and betaIII-tubulin were prognostic factors after platinum- and taxane-based neoadjuvant chemotherapy following surgical resection.	taxane	84-90	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19	
20443070-3	2010	Low excision repair cross-complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) levels have been associated with increased sensitivity to cisplatin and gemcitabine, respectively, while reduced class III beta-tubulin expression has been associated with taxane activity.	taxane	269-275	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-49	
20443070-3	2010	Low excision repair cross-complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) levels have been associated with increased sensitivity to cisplatin and gemcitabine, respectively, while reduced class III beta-tubulin expression has been associated with taxane activity.	taxane	269-275	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	51-56